GlassScriptPhysician profile
Maria M Kennickell
NPI 1447400171
$3,710.59
in general payments reported to CMS, 2019-2025
27 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.86 · 2022: $136 · 2023: $860 · 2024: $374 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.86 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.25 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.07 | 2023-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $294.77 | 2025 | Tremfya |
| Ardelyx, INC. | $276.62 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $227.54 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $155.07 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $151.93 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $93.81 | 2022-2025 | Eohilia |
| Pfizer INC. | $68.97 | 2025 | |
| Celltrion USA INC. | $65.57 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $61.80 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $61.32 | 2025 | |
| Genzyme Corporation | $60.56 | 2025 | |
| Ferring Pharmaceuticals INC. | $53.52 | 2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $53.05 | 2023-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $51.73 | 2025 | Sutab, Suflave |
| Novo Nordisk INC | $49.14 | 2025 | Wegovy |
| Lilly USA, LLC | $39.25 | 2025 | Omvoh |
| Neuraxis, INC. | $36.69 | 2025 | |
| Boston Scientific Corporation | $34.16 | 2025 | Axonics |
| Celgene Corporation | $31.55 | 2023-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $30.07 | 2023-2024 | Linzess |
| Biocon Biologics INC | $24.70 | 2025 | Yesintek |
| Exact Sciences Corporation | $16.64 | 2025 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $16.30 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Merck Sharp & Dohme LLC | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Kennickell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.